Novel Therapies for R/R Follicular Lymphoma
A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.
CAR T for R/R FL: Treatment Considerations
Factors that should be considered when evaluating patients with relapsed/refractory follicular lymphoma for CAR T-cell therapy.
CAR T-Cell Therapy for R/R Follicular Lymphoma
Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.
ZUMA-5 in R/R Follicular Lymphoma
Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.
Treating Follicular Lymphoma With Early Progression
Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).
Emerging Therapies for R/R Follicular Lymphoma
An overview of novel therapies under investigation for the treatment of relapsed/refractory follicular lymphoma and special considerations regarding treating patients with newer, novel agents in the community setting.
Case Discussion: 68-Year-Old With R/R Follicular Lymphoma
A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.
R/R Follicular Lymphoma: Testing for EZH2
Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.
EZH2 Inhibition in R/R FL: Safety & Efficacy Data
Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.
Tazemetostat for R/R Follicular Lymphoma
Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.
R2 Regimen for R/R Follicular Lymphoma
An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.
PI3K Inhibitors for R/R Follicular Lymphoma
Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.
R/R Follicular Lymphoma: Third-Line Treatment Options
Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.
Transplantation for R/R Follicular Lymphoma
The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.
MRD Testing in R/R Follicular Lymphoma
Drs Caron A. Jacobson and Krish Patel comment on NGS (next-generation sequencing) and MRD (minimal residual disease) testing in relapsed/refractory follicular lymphoma.
Role of Rebiopsy in R/R Follicular Lymphoma
The rationale for rebiopsying patients who have relapsed/refractory follicular lymphoma and the types of molecular information that can be applied to treatment decisions.
R/R Follicular Lymphoma: Second-line Treatment Selection
Factors that hematologist-oncologists need to consider when selecting second-line therapy for relapsed follicular lymphoma.
R/R Follicular Lymphoma: Patient Prognosis
Insight regarding the prognosis for patients with follicular lymphoma who relapse and impact of treatment sequencing on this trajectory.
MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML
Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome
Orca-T Demonstrates Feasibility in Older Patients With Hematologic Malignancies
Second-Line Axi-Cel Prolongs Survival Over SOC in Elderly Patients With R/R LBCL
2 Clarke Drive Cranbury, NJ 08512